Evaluation of Therapeutic Target Gene Expression Based on Residual Cancer Burden Classification After Neoadjuvant Chemotherapy for HER2-Negative Breast Cancer

摘要

Patients with residual disease usually have a poor prognosis after standard neoadjuvant chemotherapy for breast cancer. We explored novel therapeutic targets and potential additional adjuvant treatments for patients with residual disease after standard neoadjuvant chemotherapy and found therapeutic targets by estrogen receptor status.